ZOTEFOAMS PLC — Director's Dealing 2018

Jun 4, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2587Q

Zotefoams PLC

04 June 2018

Zotefoams plc

(the 'Company')

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs

On 31 May 2018, the Company received notice of exercise and sale for tax of nil cost options granted over ordinary shares of 5 pence each ('Shares') under the Company's 2012 Deferred Bonus Share Plan ('DBSP') and 2007 Long-Term Incentive Plan ('LTIP') by Mr D B Stirling, Chief Executive Officer, as follows:

Director	LTIP	DBSP	Sold for tax	Sale price (£)	Balance retained
D B Stirling	45,532	8,668	25,526	£5.65	28,674

Awards granted under the LTIP vest subject to the satisfaction of performance targets over the three-year performance period.  The level of vesting for awards granted in 2015 was 57.95%, which was then increased to reflect the dividends paid during the performance period.

Awards granted under the DBSP vest three years from grant, subject to satisfaction of service conditions.  The awards were increased to reflect the dividends paid during the restricted period.

Following these transactions, which took place on 31 May 2018, Mr Stirling is beneficially interested in the following number of Shares:

Director	Number of Shares¹	% of ISC
D B Stirling	446,193	0.92%

¹ Includes Partnership Shares, Dividend Shares and vested Matching Shares under the Company's Share Incentive Plan.

The Notification of Dealing Form for Mr Stirling can be found below.

This notification is made in accordance with the Market Abuse Regulation.

Enquiries:

Alex Small

Group Company Secretary

Zotefoams plc

04 June 2018

020 8664 1600

About Zotefoams plc:

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology.  Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide.  Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets.  In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

www.zotefoams.com

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

ZOTEFOAMS PLC

DEALING NOTIFICATION FORM

FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: David Stirling

2.

Reason for the notification

a)

Position/status: Group CEO

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise and retention under the Long-Term Incentive Plan

c)

Price(s) and volume(s):

Price(s)	Volume(s)
£0.00	24,090

d)

Aggregated information:

Aggregate Price	Aggregate Volume	Aggregate Total
£0.00	24,090	£0.00

e)

Date of the transaction: 31 May 2018

f)

Place of the transaction: XLON

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise and sale under the Long-Term Incentive Plan to pay the tax liability.

c)

Price(s) and volume(s):

Price(s)	Volume(s)
£5.65	21,442

d)

Aggregated information:

Aggregate Price	Aggregate Volume
£121,147.30	21,442

e)

Date of the transaction: 31 May 2018

f)

Place of the transaction: XLON

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise and retention under Deferred Bonus Share Plan

c)

Price(s) and volume(s):

Price(s)	Volume(s)
£0.00	4,584

d)

Aggregated information:

Aggregate Price	Aggregate Volume
£0.00	4,584

e)

Date of the transaction: 31 May 2018

f)

Place of the transaction: XLON

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise and sale for tax under Deferred Bonus Share Plan

c)

Price(s) and volume(s):

Price(s)	Volume(s)
£5.65	4,084

d)

Aggregated information:

Aggregate Price	Aggregate Volume
£23,076.60	4,084

e)

Date of the transaction: 31 May 2018

f)

Place of the transaction: XLON

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAKKLELXPEFF